Is there still a room for crizotinib in first-line setting in ALK-positive NSCLC patients?

3 / 39

Treatment evolution in ALK population
Before 2017 CRIZOTINIB* PLATINUM BASED CT
After 2018 ALECTINIB**
BRIGATINIB
EMA approval
*23th Nov 2015
** 21st Dec 2017